Quick Visanne® facts

What is Visanne®?

  • Visanne contains 2 mg dienogest and is indicated for the treatment of endometriosis
  • Dienogest is a progestin that combines the properties of both 19-nortestosterone derivatives and progesterone derivatives

What makes Visanne® an excellent treatment option for endometriosis?

  • Visanne® effectively reduces both the painful symptoms of endometriosis and also underlying endometriotic lesions. It offers equivalent efficacy to gonadotropin-releasing hormone (GnRH) agonists but has a more favorable side-effect profile.
  • Visanne® is not associated with clinically relevant androgenic or hypoestrogenic effects associated with other agents such as danazol and GnRH agonists, respectively.
  • Dienogest is associated with moderate inhibition of gonadotropin secretion, which, when given continuously, leads to a hypoestrogenic environment and initial decidualisation of endometrial tissue, followed by atrophy of endometriotic lesions.
  • In addition to its effects on gonadotropin secretion, dienogest also directly inhibits proliferation of endometrium-like tissue.

How does Visanne® work?

  • Visanne reduces endometrial lesions through both local and systemic biological mechanisms. The active ingredient in Visanne, dienogest, is associated with moderate inhibition of gonadotropin-releasing hormone secretion. Disruption of this hormonal pathway leads to a decrease in the level of estradio
  • Dienogest also demonstrates a direct inhibitory effect on the proliferation of endometrium-like tissue. Additionally, preclinical evidence indicates that dienogest also shows anti-angiogenic properties.

How should Visanne ® be administered?

  • Visanne® is administered orally as a once-daily tablet.
  • Visanne® treatment can start on any day of the menstrual cycle, and must be continuous regardless of vaginal bleeding. Hormonal contraception should be stopped before initiation of Visanne®.

News

About Visanne®

Visanne® provides highly effective pain relief combined with a favourable safety and tolerability profile that allows for extended use in the treatment of endometriosis.

This section provides detailed information on the efficacy and safety profile of Visanne®, its ease of use and the extensive clinical trial program supporting the use of Visanne® in endometriosis.

About Visanne
 

This animation video will highlight the pharmacological properties and clinical profile of Visanne in the treatment of endometriosis.

Visanne Video